← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	NSTG 26 DELISTED NanoString Technologies, Inc. NSTG	88	-1	-1%	$388M
27	27 Veracyte VCYT $3.57B	88	+4	+5%	$187M
28	28 Regenxbio RGNX $473M	86	+1	+1%	$448M
29	29 Atara Biotherapeutics ATRA $96.9M	85	0	0%	$360M
30	30 Intellia Therapeutics NTLA $1.59B	85	+9	+12%	$269M
31	BLCM 31 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	84	-12	-13%	$216M
32	ATHX 32 DELISTED Athersys, Inc. Common Stock ATHX	81	+5	+7%	$32.4M
33	33 Standard BioTools LAB $258M	80	0	0%	$106M
34	34 Lakefront Biotherapeutics American Depositary Shares LKFT $1.96B	78	+14	+22%	$922M
35	AGTC 35 DELISTED Applied Genetic Technologies Corporation AGTC	77	-12	-13%	$50.6M
36	ISEE 36 DELISTED IVERIC bio, Inc. Common Stock ISEE	77	-23	-23%	$56.5M
37	NVTA 37 DELISTED Invitae Corporation NVTA	77	+12	+18%	$266M
38	38 Abeona Therapeutics ABEO $266M	70	+12	+21%	$98.6M
39	39 Invesco Biotechnology & Genome ETF PBE $429M	64	-4	-6%	$52.9M
40	40 DELISTED Adverum Biotechnologies ADVM	63	-12	-16%	$32.5M
41	41 Fate Therapeutics FATE $231M	60	+7	+13%	$86.2M
42	42 Arrowhead Research ARWR $8.26B	59	-24	-29%	$25M
43	ADAP 43 DELISTED Adaptimmune Therapeutics ADAP	56	+7	+14%	$216M
44	44 Wave Life Sciences WVE $629M	56	+7	+14%	$359M
45	45 Fortress Biotech FBIO $63.7M	54	+6	+13%	$28.8M
46	46 Voyager Therapeutics VYGR $127M	52	+5	+11%	$98.1M
47	47 Rocket Pharmaceuticals RCKT $259M	51	-16	-24%	$15M
48	48 Arbutus Biopharma ABUS $850M	50	-3	-6%	$133M
49	49 Cartesian Therapeutics RNAC $199M	48	+2	+4%	$235M
50	50 Cellectis CLLS $111M	41	+1	+3%	$136M